Actinium: Canaccord Genuity Growth Conference (Actinium Pharmaceuticals) - Aug 14, 2014 - "Bismab-A Phase I/II Results"; "Median survival was 4x greater compared to historical data for untreated patients*"; "*Median survival was 7.6 months versus 1.7 months historically for untreated patients"
P1/2 data • Oncology
|